Compare ALEMBIC PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AUROBINDO PHARMA ALEMBIC PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 17.5 18.5 94.1% View Chart
P/BV x 6.9 4.0 172.8% View Chart
Dividend Yield % 0.5 0.3 209.5%  

Financials

 ALEMBIC PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
AUROBINDO PHARMA
Mar-19
ALEMBIC PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs664830 80.0%   
Low Rs412527 78.2%   
Sales per share (Unadj.) Rs208.7333.9 62.5%  
Earnings per share (Unadj.) Rs31.040.4 76.8%  
Cash flow per share (Unadj.) Rs37.151.8 71.7%  
Dividends per share (Unadj.) Rs5.502.50 220.0%  
Dividend yield (eoy) %1.00.4 277.4%  
Book value per share (Unadj.) Rs144.2237.1 60.8%  
Shares outstanding (eoy) m188.52585.91 32.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.62.0 126.9%   
Avg P/E ratio x17.416.8 103.3%  
P/CF ratio (eoy) x14.513.1 110.6%  
Price / Book Value ratio x3.72.9 130.4%  
Dividend payout %17.76.2 286.4%   
Avg Mkt Cap Rs m101,461397,569 25.5%   
No. of employees `000NA17.9 0.0%   
Total wages/salary Rs m7,46725,849 28.9%   
Avg. sales/employee Rs ThNM10,956.9-  
Avg. wages/employee Rs ThNM1,447.7-  
Avg. net profit/employee Rs ThNM1,324.3-  
INCOME DATA
Net Sales Rs m39,347195,636 20.1%  
Other income Rs m941,553 6.0%   
Total revenues Rs m39,441197,189 20.0%   
Gross profit Rs m8,73639,519 22.1%  
Depreciation Rs m1,1526,680 17.3%   
Interest Rs m1842,626 7.0%   
Profit before tax Rs m7,49331,767 23.6%   
Minority Interest Rs m1127 40.0%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1,5687,269 21.6%   
Profit after tax Rs m5,84423,645 24.7%  
Gross profit margin %22.220.2 109.9%  
Effective tax rate %20.922.9 91.4%   
Net profit margin %14.912.1 122.9%  
BALANCE SHEET DATA
Current assets Rs m19,577153,645 12.7%   
Current liabilities Rs m14,896120,429 12.4%   
Net working cap to sales %11.917.0 70.1%  
Current ratio x1.31.3 103.0%  
Inventory Days Days90135 66.4%  
Debtors Days Days4564 71.2%  
Net fixed assets Rs m27,097103,909 26.1%   
Share capital Rs m377586 64.3%   
"Free" reserves Rs m26,811138,322 19.4%   
Net worth Rs m27,188138,908 19.6%   
Long term debt Rs m4,9931,800 277.5%   
Total assets Rs m47,778264,544 18.1%  
Interest coverage x41.713.1 318.4%   
Debt to equity ratio x0.20 1,417.6%  
Sales to assets ratio x0.80.7 111.4%   
Return on assets %12.69.9 127.0%  
Return on equity %21.517.0 126.3%  
Return on capital %23.623.8 99.0%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m19,45397,316 20.0%   
Fx outflow Rs m6,06540,589 14.9%   
Net fx Rs m13,38856,727 23.6%   
CASH FLOW
From Operations Rs m8,12016,220 50.1%  
From Investments Rs m-7,556-28,768 26.3%  
From Financial Activity Rs m59019,191 3.1%  
Net Cashflow Rs m1,1536,656 17.3%  

Share Holding

Indian Promoters % 74.1 54.1 137.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 8.0 36.5%  
FIIs % 9.1 27.7 32.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.2 136.3%  
Shareholders   49,328 69,601 70.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FDC  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - PFIZER COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS